Format

Send to

Choose Destination
See comment in PubMed Commons below
Expert Opin Investig Drugs. 2011 Feb;20(2):305-7. doi: 10.1517/13543784.2011.550873. Epub 2011 Jan 5.

The use of single-agent dasatinib in molecularly unselected non-small-cell lung cancer patients.

Author information

1
University of Wisconsin Comprehensive Cancer Center, Department of Human Oncology, Madison, Wisconsin, WI 53705, USA.

Abstract

A Phase II study of the Src family kinase (SFK) inhibitor dasatinib was recently reported in molecularly unselected patients with metastatic NSCLC. SFK inhibition has a strong rationale as a clinical strategy in NSCLC. The reviewed study unfortunately showed disappointing activity as monotherapy in this molecularly unselected patient cohort and toxicity in terms of pleural effusion was problematic. Therefore, dasatinib as monotherapy in this setting does not appear promising. Nonetheless, the reviewed study may be used in conjunction with other studies of dasatinib in NSCLC to identify patients more likely to benefit from dasatinib either as monotherapy or in combination with other agents. Future studies of dasatinib in NSCLC should examine the agent in combination with EGFR inhibitors and/or cytotoxic chemotherapies.

PMID:
21204748
PMCID:
PMC3303592
DOI:
10.1517/13543784.2011.550873
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Taylor & Francis Icon for PubMed Central
    Loading ...
    Support Center